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Brief Definit ive Report
Accumulation of amyloid B (AB) peptide in 
the brain is hypothesized to initiate pathogenic 
cascades that lead to Alzheimer’s disease (AD; 
Golde et al., 2011; Holtzman et al., 2011). 
Therapeutic strategies to inhibit AB accumula-
tion, such as AB immunotherapy, are currently 
being tested as disease-modifying therapies 
(Golde et al., 2011; Holtzman et al., 2011). Se-
quential proteolytic cleavages of AB precursor 
protein (APP) by B- and G-secretase produce 
the AB peptide. Although rare, early-onset AD 
mutations in the APP, presenilin 1 (PS1), and 
PS2 genes have supported the critical role of 
AB in AD pathogenesis, the d4 allele of apolipo-
protein E (APOE) gene is the strongest genetic 
risk factor for the common late-onset form of 
AD, and the d2 allele is protective (Kim et al., 
2009a). Among several mechanisms proposed 
to explain the effects of apoE on AD pathogen-
esis, prevailing evidence suggests that apoE’s 
effect on AB accumulation may be the major 
mechanism (Kim et al., 2009a). ApoE appears 
to affect AB accumulation by modulating both 
AB aggregation and clearance (Ma et al., 1994; 
Wisniewski et al., 1994; Castano et al., 1995; 
Sadowski et al., 2006; Deane et al., 2008; Jiang 
et al., 2008; Castellano et al., 2011). Along 
with other amyloid-associated proteins, apoE 
is found in amyloid plaques (Namba et al., 1991; 
Wisniewski and Frangione, 1992). In this study, 
we hypothesized that after peripheral adminis-
tration of monoclonal anti-apoE antibodies, 
the small fraction of anti-apoE antibodies that 
enter the brain would bind to apoE in plaques 
and decrease AB accumulation by activating 
microglia-mediated clearance of AB aggregates, 
similar to what has been described for certain 
anti-AB antibodies (Bard et al., 2000; Brody 
and Holtzman, 2008).
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The apolipoprotein E (APOE) b4 allele is the strongest genetic risk factor for Alzheimer’s 
disease (AD). The influence of apoE on amyloid B (AB) accumulation may be the major 
mechanism by which apoE affects AD. ApoE interacts with AB and facilitates AB fibrillogen-
esis in vitro. In addition, apoE is one of the protein components in plaques. We hypothesized 
that certain anti-apoE antibodies, similar to certain anti-AB antibodies, may have antiamy-
loidogenic effects by binding to apoE in the plaques and activating microglia-mediated 
amyloid clearance. To test this hypothesis, we developed several monoclonal anti-apoE 
antibodies. Among them, we administered HJ6.3 antibody intraperitoneally to 4-mo-old male 
APPswe/PS1$E9 mice weekly for 14 wk. HJ6.3 dramatically decreased amyloid deposition by 
60–80% and significantly reduced insoluble AB40 and AB42 levels. Short-term treatment 
with HJ6.3 resulted in strong changes in microglial responses around AB plaques. Collectively, 
these results suggest that anti-apoE immunization may represent a novel AD therapeutic 
strategy and that other proteins involved in AB binding and aggregation might also be a 
target for immunotherapy. Our data also have important broader implications for other 
amyloidosis. Immunotherapy to proteins tightly associated with misfolded proteins might 
open up a new treatment option for many protein misfolding diseases.
© 2012 Kim et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
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lysates from apoe KO mice were used as negative controls. 
Among four HJ antibodies tested, HJ6.3 antibody (IgG2b iso-
type) gave the strongest signal in Western blotting (Fig. 1 A). 
When the membranes were overexposed, other antibodies also 
recognized apoE (Fig. 1 B). For sandwich ELISA application, 
anti-apoE antibody (WUE4) was used as a capture antibody, 
and then a different concentration of lipid-free apoE protein 
(0, 0.25, 0.74, 2.22, 6.67, 20, 60, and 180 ng/ml) was added to 
RESULTS AND DISCUSSION
Generation and characterization of anti-apoE antibodies
To characterize anti-apoE antibodies, we evaluated their per-
formance in Western blotting, ELISA, immunohistochemistry, 
and immunoprecipitation. For Western blotting application, 
cortical tissues from wild-type C57BL6/CBA background 
mice were lysed with radioimmunoprecipitation assay (RIPA) 
buffer and used for detection of apoE protein. Cortical tissue 
Figure 1. Characterization of anti-apoE antibodies. Four different anti-apoE antibodies were tested for their ability to recognize apoE in Western 
blotting (A and B), ELISA (C), immunohistochemistry (D–H), and immunoprecipitation (I). (A and B) Cerebral cortical tissues from wild-type and apoe KO 
mice were lysed with RIPA buffer and equal amounts of total proteins were loaded to each well. In B, the membranes shown in A were overexposed to 
show a weak apoE band in the membranes probed with HJ6.1, HJ6.2, and HJ6.4 antibody. (C) ELISA plates were coated with anti-apoE antibody (WUE4), 
and each biotinylated HJ antibody was used as a detection antibody. Optical density at 650 nm was measured with a series of different apoe concentra-
tions. (D–G) Biotinylated HJ antibody was used as a primary antibody in the immunohistochemical staining with APPswe/PS1$E9 mice brain tissues.  
Bar, 50 μm. (H) Biotinylated HJ6.3 antibody was used as a primary antibody in the immunohistochemical staining with brain tissues from apoE-deficient  
APPswe/PS1$E9 mice. Bar, 50 μm. (I and J) Cerebral cortical tissues from wild-type mice were lysed with RIPA buffer, and the RIPA lysates were used for 
immunoprecipitation with each HJ antibody. ApoE proteins left in the supernatant of postimmunoprecipitation (Post-IP) solution (I) and eluted from 
protein G–Sepharose beads (J) were detected with a polyclonal anti-apoE antibody (EMD Millipore).
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(Fig. 1 H). For immunoprecipitation application, each HJ anti-
body was first covalently conjugated to Sepharose beads and 
then incubated with 1% Triton X-100 cortical tissue lysates. 
The supernatants from immunoprecipitation (Fig. 1 I) and the 
eluents from the Sepharose beads (Fig. 1 J) were used in West-
ern blotting to assess efficiency of immunoprecipitation. Levels 
of apoE were measured using a polyclonal anti-apoE antibody 
(EMD Millipore) by Western blotting. HJ6.3 antibody was the 
only antibody that was able to bind to apoE in cortical tissue 
lysates, resulting in successful immunoprecipitation.
Anti-apoE immunotherapy inhibits  
amyloid accumulation in the brain
Given its ability to detect apoE in amyloid plaques (Fig. 1 F), 
we selected HJ6.3 antibody for anti-apoE immunization ex-
periments. To determine whether anti-apoE antibody would 
have an antiamyloidogenic effect, we injected PBS or anti-
apoE antibody (HJ6.3) weekly at 10 mg of antibody/kg of 
body weight per dose. 4-mo-old male APPswe/PS1$E9 mice 
were intraperitoneally injected for 14 wk. Brain tissues were 
processed for histochemical and biochemical analyses. Quanti-
tative analyses of anti-AB immunostaining (Fig. 2, A and B) 
each well in the ELISA plates. Each biotinylated HJ antibody 
was used as a detection antibody in the sandwich ELISA for-
mat (Fig. 1 C). Although all HJ6 antibodies recognized apoE 
in the ELISA, HJ6.1 antibody (IgG1 isotype) generated the 
strongest signals. Although HJ6 antibodies were initially 
screened based on their recognition of purified, astrocyte-
secreted, lipidated apoE lipoprotein particles, all of them also 
recognized lipid-free apoE (Fig. 1, A–C).
To determine whether HJ antibodies can detect apoE in 
amyloid plaques in the brain, we stained brain tissue sections 
from amyloid plaque–bearing 7-mo-old APPswe/PS1$E9 
mice (Jankowsky et al., 2004; Fig. 1, D–G). HJ6.3 antibody 
was the only antibody that recognized apoE associated with 
amyloid plaques and in astrocytes, which are the major pro-
ducers of apoE in the brain (Kim et al., 2009a; Fig. 1 F). To 
evaluate the specificity of HJ6.3 antibody to apoE, we used 
cortical tissues from APPswe/PS1$E9 mice that lacked the 
apoe gene (APP/PS1/apoe/ mice) as negative controls. When 
HJ6.3 antibody was used as a primary antibody in the immuno-
histochemical staining, it did not give any detectable signal 
with the tissues from APP/PS1/apoe/ mice, thereby validat-
ing the specificity of HJ6.3 antibody to apoE in tissue sections 
Figure 2. Reduction of AB plaque depositions 
by anti-apoE immunotherapy. 4-mo-old male  
APPswe/PS1$E9 mice were intraperitoneally injected 
with PBS vehicle or anti-apoE antibody (HJ6.3) weekly 
for 14 wk. (A and B) Brain sections from 7-mo-old 
mice were immunostained for AB plaques with anti-
AB antibody (82E1-biotin). Bar, 250 μm. The extent of 
AB plaque load was quantified in cortex (C) and hip-
pocampus (D). The number of plaques per unit area 
was quantified in cortex (E) and hippocampus (F). 
n = 7 for PBS group; n = 18 for HJ6.3 group. To 
determine the statistical significance (***, P < 0.001), 
a two-tailed Student’s t test was used. Variance in all 
graphs represents SEM.
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levels were observed in the cortex (Fig. 4, A and B) and hip-
pocampus (Fig. 4, C and D) of mice treated with HJ6.3 
antibody. Collectively, our results clearly demonstrate that 
anti-apoE antibody HJ6.3 treatment dramatically inhibits AB 
aggregation and amyloid accumulation in the brain.
Anti-apoE antibody treatment does not affect  
levels of cholesterol and apoE
ApoE lipoprotein plays a key role in the receptor-mediated 
endocytosis of lipoprotein particles in the plasma, thereby 
regulating plasma cholesterol levels (Kim et al., 2009a). It 
is conceivable that long-term treatment of anti-apoE anti-
body may alter plasma cholesterol metabolism by interfer-
ing with a normal function of apoE in the periphery. To 
assess this potential concern, we measured total cholesterol 
levels in the plasma from the APP/PS1 mice treated for 14 wk. 
No significant difference in total cholesterol levels was ob-
served between the PBS-treated and HJ6.3 antibody-treated 
groups (PBS group, 151.0 ± 13.82 mg/dl; HJ6.3 group, 
140.0 ± 12.45 mg/dl; P = 0.598; 95% confidence interval, 
demonstrated that AB plaque load in the cortex (Fig. 2 C) and 
hippocampus (Fig. 2 D) was markedly decreased by HJ6.3 
antibody treatment, compared with the PBS-treated control 
group. There was a strong 70–80% reduction in AB plaque 
load in the cortex (Fig. 2 C) and hippocampus (Fig. 2 D). 
HJ6.3 treatment also significantly decreased the number of 
plaques per area in the cortex (Fig. 2 E) and hippocampus 
(Fig. 2 F). To further characterize the structural nature of the 
deposited AB plaques, brain sections were stained with X-34 
dye that selectively recognizes only fibrillar AB deposits (Fig. 3, 
A and B). Consistent with the anti-AB antibody staining results 
(Fig. 2), the HJ6.3-treated group had significantly less X-34–
positive fibrillar plaque load (Fig. 3, C and D) and a decrease in 
the number of fibrillar plaques per area (Fig. 3, E and F) in the 
cortex (Fig. 3, C and E) and hippocampus (Fig. 3, D and F). 
To determine the effect of HJ6.3 antibody on insoluble AB 
accumulation, we performed AB end-specific ELISA. Cortical 
and hippocampal tissues were sequentially homogenized with 
PBS and 5 M guanidine HCl buffer. Significant reductions in 
insoluble AB40 (Fig. 4, A and C) and AB42 (Fig. 4, B and D) 
Figure 3. Attenuation of fibrillar amyloid 
accumulations by anti-apoE immunotherapy. 
(A and B) Brain sections from male mice injected 
with PBS or HJ6.3 antibody were stained with X-34 
dye that recognizes only fibrillar plaques with a 
B-sheet conformation. Bar, 150 μm. The extent of 
fibrillar plaque load was quantified from cortex  
(C) and hippocampus (D). The number of fibrillar 
plaques per unit area was quantified from cortex  
(E) and hippocampus (F). n = 7 for PBS group;  
n = 18 for HJ6.3 group. Variance in all graphs  
represents SEM.
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(Fig. 5, A and B). Previous studies demonstrated that fibrillar 
amyloid plaques are strongly associated with the activation of 
microglia (Lucin and Wyss-Coray, 2009). Because we used 
9-mo-old APPswe/PS1$E9 mice with preexisting fibrillar 
plaques (Jankowsky et al., 2004), we calculated HJ6.3-induced 
microglial activation after normalizing with fibrillar plaque 
load. Fibrillar plaque load was measured from subsequent 
adjacent sections (50 μm apart) stained with the fibrillar amy-
loid–detecting dye X-34. Quantitative analyses indicted that 
anti-apoE antibody HJ6.3 significantly increased CD-45 stain-
ing associated with amyloid plaques (Fig. 5 C), suggesting 
HJ6.3-mediated recruitment of microglia around plaques.
To better characterize the type of inflammatory response 
mediated by HJ6.3 antibody, we measured levels of several 
cytokines in cortical tissue lysates. Using Rodent Cytokine 
MAP kit (Myriad RBM), we measured the levels of IFN-G, 
IL-1A, IL-1 B, IL-4, IL-6, IL-10, IL-12p70, and tumor ne-
crosis factor A. Although most cytokines in the cortex were 
below detection limit, levels of IFN-G, IL-1A, and IL-10 
were reliably measured. Although the levels of proinflam-
matory cytokines (IFN-G and IL-1A) were significantly de-
creased by anti-apoE antibody treatment (Fig. 5, D and E), 
the antiinflammatory cytokine IL-10 showed a trend toward 
increased level (PBS group, 10.88 ± 1.061 pg/mg of total 
protein; HJ6.3 group, 13.65 ± 1.855 pg/mg of total protein; 
P = 0.21). In the 14-wk long-term treatment experiments, 
HJ6.3 treatment did not cause any significant change in the 
cytokine levels (unpublished data). No effect on cytokine is 
likely caused by an extended time delay (10 d) between the 
last antibody injection and tissue collection in the long term 
treatment paradigm. Collectively, these data suggest that anti-
apoE immunotherapy acutely modulates inflammatory re-
sponse of microglia to amyloid plaques.
34.16–56.23). In addition, there was no significant change 
in apoE levels between two groups (cortex apoE in PBS 
group, 6.026 ± 0.1783 ng/mg of wet brain weight; cortex 
apoE in HJ6.3 group, 6.507 ± 0.3107 ng/mg of wet brain 
weight; P = 0.25; 95% confidence interval, 1.340–0.3773; 
plasma apoE in PBS group, 207.1 ± 25.01 μg/ml; plasma 
apoE in HJ6.3 group, 192.3 ± 13.54 μg/ml; P = 0.58; 95% 
confidence interval: 39.21–68.90). Body weights of both 
groups were similar (PBS group, 45.57 ± 0.8226 g; HJ6.3 
group, 45.26 ± 1.154 g; P = 0.8340; 95% confidence in-
terval: 2.691–3.314). Collectively, these data indicate 
that anti-apoE immunotherapy with HJ6.3, when given 
weekly, does not influence brain apoE, peripheral choles-
terol metabolism, and general health.
Anti-apoE antibody treatment recruits microglia around 
plaques and decreases levels of proinflammatory cytokines
Several mechanisms have been proposed to explain the bene-
ficial effects of anti-AB immunotherapy (Brody and Holtzman, 
2008; Golde et al., 2009). Among them, recruitment and 
activation of microglia triggered by antibody in the brain 
appears to be one of main underlying mechanisms (Koenig-
sknecht-Talboo et al., 2008; Wang et al., 2011). The level of 
HJ6.3 antibody detected in the brain 24 h after a single injec-
tion was 0.096 ± 0.019% of the level present in the plasma. 
To determine whether HJ6.3 antibody can increase the 
amount of microglia around plaques, we quantified CD45+ 
microglia after short-term treatment of HJ6.3 antibody (in-
traperitoneal injection 4 times every 3 d) in mice that already 
had existing plaques at 9 mo of age. Brain tissues were col-
lected 1 d after the fourth injection. To quantitatively assess 
the extent of microglial activation, we used an anti-CD45 
antibody that recognizes activated microglia around plaques 
Figure 4. Decrease of insoluble AB levels by anti-
apoE immunotherapy. Cortical and hippocampal tis-
sues from male mice injected with PBS or HJ6.3 antibody 
were first homogenized with PBS. Aggregated forms of 
AB in the PBS-insoluble pellet were solubilized with 5M 
guanidine HCl buffer. Insoluble AB40 (A) and AB42  
(B) levels in cortex were measured using an AB-end 
specific ELISA. Similarly, insoluble AB40 (C) and AB42  
(D) levels in hippocampus were measured using AB  
end-specific ELISA. n = 7 for PBS group; n = 18 for  
HJ6.3 group. Variance in all graphs represents SEM.
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proinflammatory cytokines, leading to reduction in amyloid 
accumulation.
Considering the direct effects of apoE on AB clearance 
and aggregation (Kim et al., 2009a), other mechanisms could 
theoretically be involved in anti-apoE antibody-mediated re-
duction in amyloid accumulation. Several studies demon-
strated that apoE modulates AB clearance (Kim et al., 2009a). 
Binding of apoE to AB may slow down AB clearance in the 
brain, therefore increasing AB accumulation. This possibility 
is supported by the fact that mice lacking apoE have faster AB 
clearance, relative to apoE-expressing mice (DeMattos et al., 
2004). Anti-apoE antibody may bind to soluble apoE, thereby 
attenuating apoE-mediated impairment of AB clearance. 
Another mechanism could be related with the direct influence 
of apoE on AB fibrillogenesis. Previous studies have demon-
strated that apoE increases AB fibrillogenesis under certain 
in vitro AB aggregation conditions (Ma et al., 1994; Wisniewski 
et al., 1994; Castano et al., 1995). Anti-apoE antibody could 
physically interfere with the interaction between apoE and 
AB, thereby decreasing the fibrillogenic effect of apoE on AB. 
A similar strategy preventing the interaction between apoE 
and AB has already been successfully used to attenuate AB 
toxicity and amyloid deposition (Sadowski et al., 2006). Similar 
mechanisms may mediate antiamyloidogenic phenotypes ob-
served in apoe haploinsufficient mouse models (Bien-Ly et al., 
2012; Kim et al., 2011). In the current study, we administered 
anti-apoE antibody to 4-mo-old male APPswe/PS1$E9 
mice when they had just started to develop amyloid deposi-
tion. Previous studies have demonstrated that anti-AB anti-
bodies can effectively decrease amyloid accumulation when 
they are given preventatively, but they are less effective in a 
treatment mode (Brody and Holtzman, 2008; Golde et al., 
2009). In future studies, it will be important to determine 
whether anti-apoE antibodies will prevent the detrimental 
effects of apoE and have therapeutic effects on pathology, 
even when the treatment begins after significant amyloid de-
position occurred in the brain.
In the current study, we hypothesized that anti-apoE anti-
bodies may have anti-amyloidogenic effects, by binding to 
apoE in amyloid plaques and activating microglia-mediated 
AB clearance. Weekly intraperitoneal injection of anti-apoE 
antibody HJ6.3 over 14 wk dramatically reduced amyloid 
plaque deposition and insoluble AB accumulation in the cor-
tex and hippocampus, without altering plasma cholesterol 
levels. These data suggest that anti-apoE immunization strat-
egy may be further explored as a potential therapeutic strat-
egy in AD. In addition, our finding may help further elucidate 
the precise function of apoE in AD pathogenesis. Previously, 
a variety of different anti-AB antibodies have been shown 
to inhibit AB accumulation in mouse models of AB amyloi-
dosis, and they are considered promising disease-modifying 
therapies (Brody and Holtzman, 2008; Golde et al., 2009). 
However, passive immunotherapy targeting other compo-
nents of AB plaques, such as apoE, has not been previously 
considered. We demonstrate that passive immunization against 
AB-associated protein, apoE, can be very effective in attenu-
ating AB accumulation. Along with a recent study using active 
vaccination with ankyrin G (Santuccione et al., 2012), our 
finding opens up a new avenue of research to target other 
components in amyloid plaques, such as apoE, apolipoprotein 
J/clusterin, and heparin sulfate proteoglycans.
Recruitment and activation of microglia around plaques 
and subsequent AB degradation/clearance have been proposed 
as one of the mechanisms by which AB immunotherapy de-
creases amyloid levels (Bard et al., 2000; Koenigsknecht-Talboo 
et al., 2008; Wang et al., 2011). In our study, anti-apoE anti-
body HJ6.3 significantly increased CD45-positive micro-
glia around amyloid plaques and decreased proinflammatory 
cytokines. This finding suggests that anti-apoE antibody 
might modulate similar inflammatory responses, which is 
consistent with the effect of certain anti-AB antibodies 
(Bard et al., 2000; Wilcock et al., 2004). Anti-apoE anti-
bodies may recruit microglia to apoE-containing plaques, 
triggering both direct phagocytosis and the attenuation of 
Figure 5. Modulation of microglia ac-
tivity by anti-apoE antibody treatment. 
APPswe/PS1$E9 mice were intraperitoneally 
injected with PBS vehicle or anti-apoE anti-
body (HJ6.3; 10 mg/kg) 4 times every 3 d.  
(A and B) Brain sections were immunostained 
for activated microglia with anti-CD45  
antibody. Bar, 150 μm. (C) The extent of 
microglial recruitment around plaques in 
cortex was quantified after normalizing 
with X-34–positive fibrillar plaque load.  
(D and E) Levels of proinflammatory cytokines 
(IFN-G and IL-1A) in the cortex were mea-
sured by Rodent Cytokine Multi-Analyte 
Profile assay. n = 11 for PBS group; n = 9 
for HJ6.3 group. Variance represents SEM.
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Histology and quantitative analysis of AB plaques. Brain hemispheres 
were placed in 30% sucrose before freezing and cutting on a freezing sliding 
microtome. Serial coronal sections at 50-μm intervals were collected from 
the rostral anterior commissure to caudal hippocampus. Sections were 
stained with biotinylated 82E1 (anti-AB1-16) antibody (1:500 dilution; IBL 
International) or X-34 dye. Stained brain sections were scanned with a 
NanoZoomer slide scanner (Hamamatsu Photonics) at 20× magnification 
setting. For quantitative analyses of 82E1-biotin and X-34 staining, scanned 
images were exported using NDP viewer software (Hamamatsu Photonics) 
and converted to 8-bit grayscale using ACDSee Pro 2 software (ACD Sys-
tems). All converted images were uniformly thresholded to highlight plaques, 
and then analyzed by “Analyze Particles” function in the ImageJ software 
(National Institutes of Health). Identified objects after thresholding were in-
dividually inspected to confirm the object as a plaque or not. 3 brain sections 
per mouse, each separated by 300 μm, were used for quantification. These 
sections correspond approximately to sections at Bregma 1.7, 2.0, and 
2.3 mm in the mouse brain atlas. The mean of three sections was used to 
represent a plaque load for each mouse. For analysis of AB plaque in the cor-
tex, the cortex immediately dorsal to the hippocampus was assessed. All 
analyses were performed in a blinded manner.
Quantitative analysis of CD45 staining. Brain sections cut with a freez-
ing sliding microtome were immunostained with anti-CD45 antibody 
(1:500 dilution; AbD Serotec). Stained brain sections were scanned with a 
NanoZoomer slide scanner (Hamamatsu Photonics) at 40× magnification 
setting. The percent area covered by CD45 staining was analyzed in the cor-
tex by using NDP viewer, ACDSee Pro 2, and ImageJ softwares, as described 
in the previous section. Three brain sections per mouse, each separated by 
300 μm, were used for quantification. The mean of three sections was used 
to estimate the area covered by immunoreactivity. All analyses were per-
formed in a blinded fashion after stained images were thresholded to mini-
mize false-positive signals.
Measurement of IFN-G and IL-1A. 9-mo-old male APPswe/PS1$E9 
mice were intraperitoneally injected 4 times every 3 d, and brain tissues were 
collected 24 h after the last injection. Cerebral cortical tissues were lysed 
by sonication (3-s pulse, 5 times, 35% amplitude) with lysis buffer (50 mM 
Tris-HCL, 2 mM EDTA, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 0.25 mM 
phenylmethanesulfonyl fluoride, pH 7.4). Homogenates were centrifuged 
for 10 min at 14,000 RPM. Supernatants were used to measure IFN-G and 
IL-1A levels using Rodent Cytokine Multi-Analyte Profile (Myriad RBM).
AB and apoE ELISA. Cortical and hippocampal tissues were sequentially 
homogenized with PBS and 5 M guanidine buffer in the presence of 1X 
protease inhibitor mixture (Roche). The levels of insoluble AB in a 5-M 
guanidine fraction were measured by sandwich ELISA. For AB ELISA, HJ2 
(anti–AB35-40) and HJ7.4 (anti–AB37-42) were used as capture antibodies, 
and HJ5.1-biotin (anti–AB13-28) was used as the detection antibody. ApoE 
levels in the plasma and cortical tissue PBS lysates were measured using apoE 
ELISA. HJ6.2 and HJ6.3 antibodies were used for capture and detection, re-
spectively. Pooled C57BL/6J plasma was used as a standard for murine apoE 
quantification (Kim et al., 2009b).
Total cholesterol assay. 10 μl of plasma from each mouse was mixed 
with 1 ml of Color Reagent (Wako Chemicals USA), containing 1.6 U/ml 
cholesterol ester hydrolase, 0.31 U/ml cholesterol oxidase, 5.2 U/ml 
peroxidase, 0.19 mmol/l 4-aminoantipyrine, 4.4 U/ml ascorbate oxidase, 
and 0.95 mmol/l 3,5-dimethoxy-N-ethyl-N-(2-hydroxy-3-sulfopropyl) 
aniline sodium. After 5 min incubation at 37°C, absorbances of samples 
and standards were measured at 600 nm. Total cholesterol levels were 
calculated based on the standard curve.
Statistical analyses. To determine the statistical significance (*, P < 0.05; 
**, P < 0.01; ***, P < 0.001), two-tailed Student’s t test was used (GraphPad 
Prism 5.0), after testing the equal variance test (Levene median test) and 
MATERIALS AND METHODS
Generation of antibodies. To generate monoclonal anti-apoE antibodies, 
we first isolated apoE lipoprotein particles from primary astrocytes cultured 
from C57BL6 mice (The Jackson Laboratory) using an apoE antibody (EMD 
Millipore) immunoaffinity column. Purified, astrocyte-secreted, lipidated 
apoE lipoprotein particles were injected with complete Freund’s adjuvant 
into apoe KO mice (The Jackson Laboratory). For an initial screening of anti-
bodies, supernatants from hybridoma cells (Y2,000 wells) were added to 
96-well plates coated with purified, astrocyte-secreted, lipidated apoE lipo-
protein particles. Using anti–mouse IgG-horseradish peroxidase as a detec-
tion antibody, we initially identified 36 clones, and then subcloned them to 
find those that performed well in several biochemical and immunohisto-
chemical assays. Antibody isotype was determined using a mouse monoclo-
nal antibody isotyping kit (GE Healthcare).
Immunoblotting. Cerebral cortical tissues from wild-type and apoe KO 
mice were lysed with RIPA lysis buffer (1% NP-40, 1% sodium deoxycho-
late, 0.1% SDS, 25 mM Tris-HCl, and 150 mM NaCl) in the presence of 1X 
protease inhibitor mixture (Roche). Tissue homogenates were centrifuged at 
18,000 rcf for 30 min. Protein concentration in supernatants was determined 
using the BCA protein assay kit (Thermo Fisher Scientific). Equal amount of 
total proteins were run on 4–12% Bis-Tris XT gels (Bio-Rad Laboratories) 
and transferred to nitrocellulose membranes. Blots were probed with anti-
apoE antibodies HJ6.1, HJ6.2, HJ6.3, or HJ6.4, as indicated in the figure. 
Equal amount of anti-apoE antibodies were used as a primary antibody to 
detect apoE in Western blotting. Blots were simultaneously exposed for the 
same period of time.
Immunoprecipitation. Protein G–Sepharose 4 Fast Flow beads (GE 
Healthcare) were washed with ice-cold PBS and resuspended in ice-cold 
PBS. The washed 50% beads were then mixed with each HJ6 series anti-
bodies (0.4 μg/μl of 50% bead mixture) in the presence of 1% Triton 
X-100. Antibody beads were prepared by covalently binding HJ6 antibodies 
to protein G–Sepharose 4 Fast Flow beads. Freshly prepared dimethyl 
pimelimidate in 0.2 M triethanolamine (pH, 8.2; Sigma-Aldrich) was 
added to the beads to cross-link. The beads were then washed once with 
50 mM Tris (pH, 7.5) to stop the cross-linking reaction. Brain cortex 
samples were lysed in 1% Triton X-100 lysis buffer (Triton X-100, 150 mM 
NaCl, 50 mM Tris-HCl, 1X complete protease tablet [Roche]). After 
centrifugation at 18,000 rcf for 30 min, the supernatant was collected 
and used for subsequent immunoprecipitation steps. The precleared 
lysates were then tumble incubated with HJ antibody-conjugated beads 
for immunoprecipitation.
Immunization of mice. 4-mo-old male APPswe/PS1$E9 mice (Jankowsky 
et al., 2004) were intraperitoneally injected weekly for 14 wk with PBS 
or anti-apoE antibody (HJ6.3) at 10 mg of antibody/kg of body weight 
dose. Working stock of antibody was freshly prepared on the date of in-
jection at 1 mg/ml concentration. Brain tissues were collected 10 d after 
the last injection. For a short-term experiment, nine-month-old male 
APPswe/PS1$E9 mice were intraperitoneally injected 4 times every 3 d, 
and brain tissues were collected 24 h after the last injection. All animal 
experiments were approved by the animal study committee at Washington 
University in St. Louis.
Measurement of HJ6.3 antibody levels in cerebral cortex and plasma. 
4-mo-old APPswe/PS1$E9 mice were intraperitoneally injected one time 
with biotinylated anti-apoE antibody (HJ6.3) at 10 mg of antibody/kg of 
body weight dose. After perfusion, cerebral cortical tissues were collected 
24 h after injection, and then sonicated with PBS (100 mg of wet weight/ml of 
PBS). PBS lysates and plasma samples were loaded to anti–mouse IgG antibody-
coated plate (10 μg/ml; Jackson ImmunoResearch Laboratories), and biotinyl-
ated HJ6.3 antibody was detected with poly-horseradish peroxidase streptavidin 
(Thermo Fisher Scientific) and Super Slow 3,3,5,5-tetramethylbenzidine 
(Sigma-Aldrich).
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normality test (Kolmogorov-Smirnov test; SigmaStat 3.0.). Variability of the 
measurements was reported as SEM.
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